NAFDAC Approves Malaria Vaccine, Nigeria To Receive 100,000 Doses
The National Agency for Food and Drug Administration and Control has approved the R21 malaria vaccine manufactured by the Serum Institute of India.
The Director General of NAFDAC, Prof. Mojisola Adeyeye, disclosed this at a press briefing in Abuja.
This makes Nigeria the second country, after Ghana, to approve the new malaria vaccine developed at the University of Oxford.
Prof. Adeyeye said the vaccine was indicated for the prevention of clinical malaria in children from five to 36 months of age.
She said the country is expected to get at least 100,000 doses of the vaccine in donations soon before the market authorisation, when arrangements would be made with the National Primary Health Care Development Agency.
Adeyeye said, “NAFDAC in exercising its mandate as stipulated by its enabling law, NAFDAC Act CapN1, LFN 2004, is granting registration approval for R21 malaria vaccine (recombinant, adjuvanted) manufactured by Serum Institute of India Pvt. Ltd.
“The Marketing Authorisation Holder is Fidson Healthcare Ltd in line with the agency’s Drug and Related Products Registration Regulation 2021.
“The R21 malaria vaccine is an adjuvanted protein vaccine presented as a sterile solution. A dose, which is 0.5ml, is composed of R21 malaria antigen 5µg and Matrix-M1 50µg as an adjuvant filled in a vial as a ready-to-use liquid formulation for intramuscular injection.
“The vaccine is indicated for the prevention of clinical malaria in children from five months to 36 months of age. The storage temperature of the vaccine is 2-8 °C.”
She said the dossier of the vaccine was subjected to independent review at two levels.
She said the dossier was reviewed by NAFDAC’s Vaccine Advisory Committee independently, using standards of the World Health Organisation across relevant domains.
She said, “NEVAC members reviewed all sections independently using best review practices and met physically in plenary to assess and debate the reviews by sections, raised queries, and made recommendations accordingly.
“Overall, the assessment was scored as adequate, fully compliant with standards, and the report was submitted to the Director General.
“The review of NAFDAC’s committee has always been guided by the same international standards and best practices with the same modality of an independent review by members followed by long hours of plenary where a rigorous assessment of each review took place.
“The committee also independently scored the assessment as satisfactory and forwarded it to the Director General.”
According to her, the R21 malaria vaccine dossier complied substantially with the best international standards with which the dossier was benched-marked.
Four African countries accounted for just over half of all malaria deaths worldwide – Nigeria (31.3%), the Democratic Republic of the Congo (12.6%), United Republic of Tanzania (4.1%) and Niger (3.9%).
In Nigeria, 97 per cent of the population are at risk of malaria.
Malaria accounts for 30 per cent of infant mortality and 11 per cent of mortality cases, recorded in the country.
As of 2020, Nigeria shouldered 31.9% of global malaria deaths and ranked as the most malaria-burdened country in Africa.
in 2021, the Federal Government launched the Malaria Eradication Fund to strengthen the country’s public health system, so as to respond to the challenge posed by the disease.
Punch/Oyenike Oyeniyi
